Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 9/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
| ▸ | AHR | P35869 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TDP2 | O95551 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11926942 | 0.80 | GAA (0.37) | MAPTHTTSMN1; SMN2NPC1GAA | |
| SCHEMBL9288562 | 0.77 | APP (0.41) | LMNAMAPTHTTBLMAPP | |
| SCHEMBL16995784 | 0.76 | BACE1 (0.38) | LMNAMAPTHTTBLMBACE1 | |
| SCHEMBL30148868 | 0.73 | BACE1 (0.38) | LMNAMAPTHTTBLMBACE1 | |
| SCHEMBL28922769 | 0.73 | BACE1 (0.38) | LMNAMAPTHTTBLMBACE1 | |
| SCHEMBL30148835 | 0.73 | BACE1 (0.41) | LMNAMAPTHTTBLMBACE1 | |
| SCHEMBL8101765 | 0.72 | LMNA (0.35) | LMNAMAPTHTTBLMBACE1 | |
| SCHEMBL6652414 | 0.71 | APP (0.40) | BACE1APPAHRSMN1; SMN2TDP2 | |
| SCHEMBL3990720 | 0.71 | APP (0.40) | BACE1APPAHRSMN1; SMN2TDP2 | |
| SCHEMBL7920247 | 0.70 | BACE1 (0.35) | LMNAMAPTHTTBLMBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921360-B2 | Heterobicycle-substituted azolyl benzene fungicides | E. I. DU PONT DE NEMOURS AND COMPANY | 2014-12-30 | — | — | US | disclosed |
| EP-2493880-B1 | HETEROBICYCLE-SUBSTITUTED AZOLYL BENZENE FUNGICIDES | DU PONT (US) | 2013-09-18 | — | — | EP | disclosed |
| EP-2493880-A1 | HETEROBICYCLE-SUBSTITUTED AZOLYL BENZENE FUNGICIDES | E. I. du Pont de Nemours and Company (US) | 2012-09-05 | — | — | EP | disclosed |
| US-20120202815-A1 | HETEROBICYCLE-SUBSTITUTED AZOLYL BENZENE FUNGICIDES | E.I.DU PONT DE NEMOURS AND COMPANY (US) | 2012-08-09 | — | — | US | disclosed |
| WO-2011059619-A1 | HETEROBICYCLE-SUBSTITUTED AZOLYL BENZENE FUNGICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202815-A1 | HETEROBICYCLE-SUBSTITUTED AZOLYL BENZENE FUNGICIDES | CBR3, CBR1, CYP2S1 | LMNA 4756/4885MAPT 4549/4885HTT 4625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.